Q3 Earnings Estimate for Climb Bio Issued By Leerink Partnrs

Key Points

• Leerink Partnrs has raised its Q3 2025 earnings per share (EPS) estimate for Climb Bio to ($0.16), indicating an improvement from their earlier forecast of ($0.19).
• Climb Bio's stock currently has a consensus rating of "Buy" with an average price target of $9.00, supported by reports from multiple analysts.
• The company recently reported earnings of ($0.13) per share, surpassing expectations and demonstrating positive momentum as shares increased by 5.5% in trading.

Climb Bio, Inc. (NASDAQ:CLYM - Free Report) - Analysts at Leerink Partnrs increased their Q3 2025 earnings per share estimates for shares of Climb Bio in a report released on Tuesday, August 12th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($0.16) per share for the quarter, up from their previous estimate of ($0.19). The consensus estimate for Climb Bio's current full-year earnings is ($1.57) per share. Leerink Partnrs also issued estimates for Climb Bio's Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.78) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at ($1.57) EPS and FY2029 earnings at ($2.54) EPS.

Climb Bio (NASDAQ:CLYM - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.06.

A number of other research analysts have also weighed in on the stock. Oppenheimer started coverage on shares of Climb Bio in a research report on Friday, June 6th. They set an "outperform" rating and a $10.00 target price for the company. Robert W. Baird initiated coverage on shares of Climb Bio in a research note on Friday. They issued an "outperform" rating and a $9.00 target price for the company. BTIG Research began coverage on shares of Climb Bio in a research note on Thursday, May 22nd. They issued a "buy" rating for the company. Finally, Baird R W raised Climb Bio to a "strong-buy" rating in a research report on Friday. Two research analysts have rated the stock with a Strong Buy rating and four have given a Buy rating to the company. According to MarketBeat.com, Climb Bio presently has a consensus rating of "Buy" and an average price target of $9.00.

Climb Bio Price Performance

NASDAQ CLYM traded down $0.09 on Friday, hitting $2.02. 837,361 shares of the stock were exchanged, compared to its average volume of 340,737. The company's 50-day moving average price is $1.43 and its two-hundred day moving average price is $1.37. The company has a market capitalization of $136.88 million, a price-to-earnings ratio of -2.89 and a beta of -0.11. Climb Bio has a 52-week low of $1.05 and a 52-week high of $8.79.

Institutional Investors Weigh In On Climb Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of CLYM. Shay Capital LLC grew its position in Climb Bio by 107.5% in the second quarter. Shay Capital LLC now owns 415,000 shares of the company's stock worth $515,000 after acquiring an additional 215,000 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Climb Bio during the second quarter valued at approximately $184,000. Diadema Partners LP grew its holdings in shares of Climb Bio by 4.8% during the second quarter. Diadema Partners LP now owns 702,135 shares of the company's stock valued at $871,000 after buying an additional 32,332 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in Climb Bio in the second quarter worth approximately $43,000. Finally, Marshall Wace LLP bought a new position in Climb Bio in the 2nd quarter worth $46,000. Institutional investors own 69.76% of the company's stock.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.